Τίτλος:
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1–7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3–4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
Συγγραφείς:
Terpos, E.
Ramasamy, K.
Maouche, N.
Minarik, J.
Ntanasis-Stathopoulos, I.
Katodritou, E.
Jenner, M.W.
Plonkova, H.
Gavriatopoulou, M.
Vallance, G.D.
Pika, T.
Kotsopoulou, M.
Kothari, J.
Jelinek, T.
Kastritis, E.
Aitchison, R.
Dimopoulos, M.A.
Zomas, A.
Hajek, R.
Περιοδικό:
Annals of Hematology
Λέξεις-κλειδιά:
bortezomib; dexamethasone; ixazomib; lenalidomide; thalidomide; antineoplastic agent; boron derivative; dexamethasone; glycine; ixazomib; lenalidomide, adult; adverse outcome; aged; anemia; Article; cancer growth; cancer recurrence; clinical effectiveness; Czech Republic; dose response; drug effect; drug efficacy; drug exposure; drug safety; dyspnea; female; gastrointestinal symptom; Greece; heart arrhythmia; heart failure; human; hypercalcemia; kidney failure; major clinical study; male; multiple myeloma; neutropenia; observational study; pancytopenia; peripheral neuropathy; priority journal; progression free survival; retrospective study; thrombosis; treatment outcome; United Kingdom; clinical trial; disease free survival; middle aged; mortality; multicenter study; multiple myeloma; phase 3 clinical trial; recurrent disease; survival rate; very elderly, Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate
DOI:
10.1007/s00277-020-03981-z
